*April 2022* Video: Jill Feldman, co-founder of the EGFR Resisters and Stage 4 lung cancer survivor since 2009, speaks about survivorship at ELCC. Even care Watch video here.
laurabbook@gmail.comJune 29, 2022
*February 2022* EGFR Resisters Co-Founder Ivy Elkins gave a presentation on “Keeping Your Work Focused on Patients" at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. This presentation was part of a special Early Career Workshop aimed at young investigators and focused on critical topics of interest to them…
laurabbook@gmail.comMarch 23, 2022
*January 2022* In this video, EGFR Resisters co-founder Jill Feldman discusses this topic with Dr. Jorge J Nieva of USC Norris Comprehensive Cancer Center.
laurabbook@gmail.comMarch 16, 2022
*January 2022* In this video, EGFR Resisters co-founders Jill Feldman and Ivy Elkins gave a presentation about the clinical trial life cycle. It starts at about 1:50.
laurabbook@gmail.comMarch 16, 2022
*December 2021* There is a growing cohort of younger adults who are being diagnosed with lung cancer under 40 years of age. Alarmingly, the research points to an increase not only in diagnosis at a young age—but particularly in women. Although the average age for a lung cancer diagnosis is…
laurabbook@gmail.comDecember 7, 2021
*November 2021* In this webinar, Dr. Mark A. Socinski, Executive Medical Director, Advent Health Cancer Institute, Orlando, FL, will explain the process of participating in a lung cancer clinical trial from beginning to end. Dr. Socinski will explain how typical lung cancer clinical trials are structured, how patients are monitored…
laurabbook@gmail.comDecember 7, 2021
*November 2021* Listen to EGFR Resisters co-founder Jill Feldman's presentation at ASTRO — innovating for clinically meaningful benefits that matter to patients. The final session of the symposium was a lively debate on randomized clinical trials versus real world data. Four speakers offered points/counterpoints for randomized clinical trials versus…
laurabbook@gmail.comNovember 12, 2021
*November 2021* RESEARCH=SURVIVAL! As you may know, we have increased our goal to $225K to keep fundraising for additional research projects that we will fund through our collaboration with LCRF in 2022. These research projects will be dedicated to EGFR+ lung cancer and hopefully lead to discoveries that will provide…
laurabbook@gmail.comNovember 12, 2021
*September 2021* EGFR Resisters co-founder Jill Feldman presented how stigmatizing words can affect patients and their families at WCLC 2021. Watch the video presentation here.
laurabbook@gmail.comNovember 11, 2021
*August 2021* It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way since the discovery of the first EGFR mutation in lung cancer in 2004.2 ,3 Even amid the challenges of the global…
laurabbook@gmail.comNovember 10, 2021
